This is a preview of subscription content, log in via an institution to check access.
References
Martinelli G, Terragna C, Zamagni E, Ronconi S, Tosi P, Lemoli RM et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 2000; 18: 2273–2281.
Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M et al. Allogeneic bone marrow transplantation in multiple myeloma: European Group for Bone Marrow Transplantation. N Engl J Med 1991; 325: 1267–1273.
Perez-Simon JA, Martino R, Alegre A, Brunet S, Urbano A, Caballero MD et al. Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Haematol 2003; 121: 104–108.
Kröger N, Schilling G, Einsele H, Liebisch P, Shimoni A, Nagler A et al. Deletion of chromosome 13q14 detected by fluorescence in situ hybridization as prognostic factor following allogeneic dose reduce stem cell transplantation in patients with multiple myeloma. Blood 2004; 103: 4056–4061.
Crawley C, Lalancete M, Szydlo R, Gilleece M, Peggs K, Mackinnon S et al. Outcomes for reduced intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the chronic leukemia working party of the EBMT. Blood 2005; 105: 4532–4539.
Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Bjorkstrand B et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209–216.
Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl I . Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 2005; 105: 317–323.
Kröger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A et al. Influence of timing allogeneic stem cell transplantation after dose-reduced melphalan/fludarabine conditioning in multiple myeloma. Biol Blood Marrow Transplant 2004; 10: 698–708.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Pérez-Simón, J., Sureda, A., Fernández-Aviles, F. et al. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia 20, 542–545 (2006). https://doi.org/10.1038/sj.leu.2404085
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404085
- Springer Nature Limited
This article is cited by
-
Extramedullary disease in multiple myeloma
Blood Cancer Journal (2021)
-
Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns
Annals of Hematology (2021)
-
Extramedullary multiple myeloma
Leukemia (2020)
-
Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation
Bone Marrow Transplantation (2020)
-
Multiple Myeloma: A Rare Haematological Cause of Nasal Septal Perforation and a Vasculitis Mimic
Indian Journal of Hematology and Blood Transfusion (2017)